Corona initiatives startups LBSPTuesday, July 14, 2020
Digitally enabled remote patient monitoring to support the COVID-19 capacity crisis
Aparito is a digital health company with a SaaS platform (Atom5) to support remote patient monitoring globally. Using patient generated data in the form of videos, wearables, photos and text, data is captured and transferred via the patient’s own smart phone / tablet and made available to clinicians and researchers in real time.
The COVID-19 crisis means that bed capacity within hospitals will stay overstretched for the time being. All efforts are now focused on A) increasing capacity and B) reducing the need for patients to be admitted e.g. through cancelling routine admissions. Additionally febrile (-feverish) patients have to be assumed as potential virus-positive, and kept isolation, because of the risk that if the patient is COVID-19 positive, [s]he risks contaminating all surrounding patients.
Aparito can collaborate with hospitals, clinicians and patients interested in this technology, and deploy our COVID-19 digital solution to offer remote patient monitoring as an alternative to scheduled hospital visits or in-patient stays for patients with chronic disease – giving real-time daily view of the data to the physicians.
For pharmaceutical companies running clinical trials, Aparito can support them in moving towards decentralised clinical trials to assure the safety of trial participants.
For any questions, please contact Cecile Ollivier (firstname.lastname@example.org or +31 663985856)
COVID-19 Research and Education at Leiden Academic Centre for Drug Research
Since the start of the Corona crisis, several COVID-19 related research and teaching projects were started at LACDR. The computational and teaching activities started right away, as well as a large-scale metabolomics screening program by Thomas Hankemeier’s group. Other experimental activities are still in the start-up phase due to the access restrictions to our labs; fortunately, these restrictions were partly removed, so we hope to proceed with full speed. The following article gives an overview on all COVID-19 related activities at LACDR.
Recent clinical studies have shown that Covid-19 patients are at an increased risk to develop life-threatening thrombotic complications. General Covid-19 guidelines therefore recommend the use of anti-coagulant drugs in order to prevent thrombosis in hospitalized patients. For Covid-19 patients at home and in high-risk groups oral anti-coagulant drugs are considered. Common side-effects to the use of oral anti-coagulant drugs are bleeding complications, which can be life-threatening at times. The ability to reverse the anti-coagulant effect of such drugs is therefore imperative for safe usage. In this setting, VarmX is developing a novel recombinant protein therapy to restore normal coagulation in patients receiving oral anticoagulant drugs, such as apixaban, rivaroxaban and edoxaban. This therapy is called VMX-C001.
Daniël Verhoef, Senior Scientist
Medical Nutrition to support rehabilitating COVID-19 patients
Many patients that were infected by SARS-COV2 have undergone hospitalization and/or were treated for prolonged times in the ICU. During this period they all have lost significant amount of muscle mass in addition to the other health problems that they encountered. A large fraction of these patients has to undergo intensive rehabilitation programs including physical exercise designed to increase muscle mass and muscle function. Vitalnext (www.vitalnext.com) has developed a medical nutrition that specifically stimulates increase in body weight (in patients that are malnourished and suffering from muscle loss) with a much higher relative amount of muscle mass than effects seen by standard medical nutrition products. Our product has also shown to be effective in increasing muscle function resulting in improved walking speed in patients that had suffered from muscle loss. Both effects (increase in muscle mass and improvement of muscle function) are potentially a huge benefit for recovering COVID-19 patients. While our product has not yet specifically been studied in COVID-19 patients it has undergone preclinical and clinical testing in other subjects with (involuntary) loss of muscle mass resulting in the effects described above. Our product complies with all pertinent regulatory European guidelines and has been notified at the competent regulatory body in The Netherlands as a Food for Special Medical Purposes (FSMP) . It will be available on the market in the course of August 2020. For further information please contact the company at email@example.com
Subsidie voor onderzoek naar medicijn dat longen en nieren beschermt tegen coronavirus
Wetenschappers van het Leids Universitair Medisch Centrum (LUMC) gaan een medicijn ontwikkelen dat schade aan de longen en de nieren door het SARS-CoV-2-virus moet voorkomen. Ze krijgen hiervoor ruim 900.000 euro subsidie van Topsector Life Sciences & Health (Health~Holland) en werken samen met LUMC spin-off Hybridize Pharma.
Lees hier het hele artikel.